Radius Health, Inc. RDUS announced positive top-line data from the phase III ATOM study which is evaluating its lead product, Tymlos (abaloparatide 80 mg subcutaneous [“SC”]) injection, for use in men ...

Radius Health (NASDAQ:RDUS) on Wednesday said it had entered into new agreements for the expansion of its Tymlos injection to treat osteoporosis - a condition in which bones become weak and brittle - ...

Label change aligns with strategic focus on postmenopausal women at high risk of fracture Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team Added ~3,000 new ...

WALTHAM, Mass., March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...

WALTHAM, Mass., March 17, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing ...

Labatec Pharma SA: Switzerland and the MENA region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco Pharmbio Korea Inc.: South Korea Biosidus: Colombia, ...

Action follows review of long-term post-marketing data for TYMLOS and PTH class of drugs BOSTON, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today ...

Unopened Tymlos pens should be stored in the refrigerator to maintain the effectiveness of the active ingredient. Once a Tymlos pen is opened, it can be stored at room temperature for up to 30 days, ...

(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis ...

ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001) Study also met secondary endpoints relating to bone mineral density changes in lumbar ...

Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M. TYMLOS exits 2019 with 52% market share in new patients1, on track for market leadership in 2020. Radius delivers ...